MAGEA1 and melanoma: Vaccination with autologous dendritic cells loaded with mRNA encoding for melanoma-specific antigens (MAGE-A1, -A3, -C2, tyrosinase, MelanA/MART-1, or gp100), and an HLA class II-targeting sequence, has also been evaluated in 30 resected stage III/IV melanoma patients [45].